The study of the effectiveness of blood clotting factor VIII, BioClot А in patients with hemophilia А complicated with hemarthrosis in major joints
Hemarthrosis are among major clinical complications of hemophilia A. According to the data provided by numerous authors, the absence of prophylactic treatment, leads to the risk of hemarthrosis in 95-100% of cases in patients with severe hemophilia A. Patients are being disabled with severe disorders of musculoskeletal system before reaching the age of majority, and in some cases in preschool period. Nowadays, replacement therapy with the use of clotting factor VIII is the only pathogenesis based method of treatment of hemophilic bleedings. Clinical and laboratory data of 10 patients were used for this study, all of patients were hospitalized to Kyiv State Center for diagnosis and treatment of abnormalities of hemostasis, Ukraine with diagnosis severe hemophilia A. All patients had hemarthrosis of a knee junction as a complication, and contained the study group. All patients signed informed consent for study participation. The age of patients ranged from 16 to 32 years. It is proved that BioClot A provides a therapeutic benefit in providing tertiary care to patients with hemophilia A with hemarthrosis of the knee joint. The emergence of immune inhibitors in response to the administration of BioClot A was not observed. It is shown that the recovery of Factor VIII activity in plasma after administration BioClot A occurs in accordance with the calculated values. The use of BioClot A by Biopharma company, allows to increase affordability of clotting factor VIII for patients with hemophilia A in Ukraine.